RCOR2 and neoplasm: To determine whether loss of CD4+ and/or CD8+ T cells is necessary for RCOR2-mediated tumor growth, we administered anti-CD4 antibody, anti-CD8 antibody, anti-CD4/CD8 antibodies or control antibody isotype intraperitoneally into tumor-bearing mice to deplete CD4+ and CD8+ T cells.